Abvc Biopharma, Inc. (ABVC): R&D Expense
$121.1K
Year ended 2025-12-31
$114.8K
Trailing 12 months to 2026-06-30
-64.4%
3-year compound annual growth
-26.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $121.1K | -32.5% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $179.3K | -83.1% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $1.06M | -60.5% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $2.69M | +168.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $1.00M | +82.6% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $549.7K | -47.6% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $1.05M | +6.1% | 2021-03-16, From 2019-01-01 |
| 2018-12-31 | $988.7K | n/c | 2020-05-15, From 2018-01-01 |
| 2017-12-31 | $3.17M | n/a | 2019-04-15, From 2017-01-01 |
| No annual figure between 2016-09-30 and 2017-12-31. | |||
| 2016-09-30 | $10.00M | n/a | 2018-01-16, From 2015-10-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $11.7K | -92.4% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $1.96M | -12.5% |
| Clene Inc. (CLNN) | 2025-12-31 | $14.01M | -30.1% |
Compare ABVC, HIND, ALLR, PVCT side by side · Screen every company in Pharmaceutical Preparations ↗